Spinal Muscular Atrophy: The Use of Functional Motor Scales in the Era of Disease-Modifying Treatment

Katarzyna Pierzchlewicz¹, Izabela Kępa¹, Jacek Podogrodzki¹, and Katarzyna Kotulska¹

Abstract
Spinal muscular atrophy (SMA) is a genetic condition characterized by progressive motoneuron loss. Infants affected by SMA type 1 do not gain developmental milestones and acutely decline, requiring ventilatory support. Several scales are used to assess motor disability and its progression in SMA. Recently, 3 disease-modifying therapies have been approved for SMA patients: nusinersen, an intrathecal antisense oligonucleotide enhancing SMN protein production by the SMN2 gene, risdiplam, also influencing the SMN2 gene to stimulate SMN production but administered orally, and onasemnogene abeparvovec-xioi, an SMN1 gene replacement therapy. Thus, the functional scales should now be applicable for patients improving their motor function over time to assess treatment efficacy. In this paper, we compare different functional scales used in SMA patients. Their usefulness in different SMA types, age groups, and feasibility in daily clinical practice is described below. Some changes in motor function assessments in SMA are also suggested.

Keywords
spinal muscular atrophy, disability, functional scale, treatment

Spinal muscular atrophy (SMA), a neuromuscular disease affecting about 1 in 7500 live births,¹-⁵ used to be the most common genetic cause of infant mortality before the introduction of disease-modifying treatment.¹-³,⁵ It is caused by a loss or mutation of the survival motor neuron 1 (SMN1) gene in more than 95% of cases. The disease is inherited in autosomal recessive mode, and carrier frequency varies between 1/47 in the Caucasian population to 1/72 in the African American population.⁵,⁶ In infants, SMA was first described in 1891 by Werdnig and independently by Hoffmann in 1893.⁷,⁸ The hallmark of the disease is the progressive muscle weakness associated with normal cognitive functions. Proximal muscle weakness and atrophy are more prominent than distal weakness, and lower extremities are more affected than upper ones.⁹ Based on the age of the first symptom presentation and the patient’s motor milestones before the disease’s onset, SMA is divided into 5 types.

Spinal muscular atrophy type 1, the so-called Werdnig-Hoffmann disease, is the most frequent (60%).¹,²,⁷,¹⁰ Infants with SMA type 1 are never able to sit independently, and their life expectancy is about 2 years in untreated patients.⁹ SMA type 1 can be divided into 3 subtypes:

a. symptoms are present at birth, frequently including joint contractures, and respiratory support is needed within the first weeks of life,

b. the onset of symptoms is after a neonatal period but before 3 months of age and head position control is never achieved,

c. symptoms appear between the third and sixth month of age, and head position control is possible.⁹,¹¹

¹ Department of Neurology and Epileptology, Children’s Memorial Health Institute, Warsaw, Poland

Corresponding Author:
Katarzyna Pierzchlewicz, Department of Neurology and Epileptology, Children’s Memorial Health Institute, Warsaw 04-730, Poland.
Email: katarzynapierszchlewicz88@gmail.com
Table 1. Types of SMA (Spinal Muscular Atrophy).2,9,12,13

| SMA type | Natural history of the disease | Age at first symptoms | Life expectancy without treatment |
|----------|-------------------------------|-----------------------|----------------------------------|
| 0        | Generalized hypotonia present prenatally or in neonates, respiratory insufficiency, failure to swallow, contractures | Prenatal (faint fetal movements) or neonatal | Approximately 6 months |
| 1        | Independent sitting never achieved, acute loss of motor functions, respiratory failure before the age of 2, early feeding problems | Before 6 months | Approximately 2 years |
| 2        | Independent walking never achieved, subacutely progressing muscle weakness, early development of scoliosis | 6-18 months | Shortened, different in various sources |
| 3        | Independent walking achieved, slowly progressing muscle weakness, associated with weakness and atrophy of different groups of muscles | 18 months-18 years | Not affected |
| 4        | Mild hypotonia, slowly progressing muscle weakness | After 18 years | Not affected |

In SMA type 2, patients gain the ability to sit, but they never walk, and their life expectancy is shortened. Patients with SMA type 3 (SMA3 or Kugelberg-Welander disease) develop the disease after gaining the ability to walk.2,3,9,12 Type 3 can be divided into 2 subtypes:

- 3a—with first symptoms before the age of 3, and
- 3b—with symptoms onset after the age of 3.9 (Table 1).

In SMA type 0, the most severe form of the disease, the symptoms can present prenatally or immediately after birth. Affected newborns present with respiratory failure and severe generalized hypotonia.

SMA type 4 presents in adulthood and is slowly progressing. SMA type 3 and 4 do not affect life expectancy.2,9 (Table 1). However, in all SM types, the symptoms progress irrevocably in untreated patients.

Given that all SMA patients decline over time, type 3 patients may at some point present with disability typical for type 2, and type 2 patients may require ventilatory support and lose the ability to sit, similar to SMA 1 patients. Therefore, SMA typing refers only to the patient’s best status ever. According to their current neurological status, patients are frequently divided into non-sitters, sitters, and walkers.14

In SMA, the causing mutation affects survival motor neuron (SMN) protein production involved in transcriptional regulation, telomerase regeneration, and cellular trafficking.15,16 In addition to the SMN1 gene, the human genome contains the SMN2 gene, which also produces SMN protein, but due to the single nucleotide substitution in exon 7, only 10-20% of SMN2 transcripts are full-length functional protein.16 Lack of SMN protein in motor neurons results in SMA symptoms. Degeneration of spinal cord motoneurons leads to improper motor innervation and muscle atrophy with axial and bulbar muscles being most severely affected.8,17 The symptoms of the disease are associated with weakness and atrophy of different groups of muscles. They include scoliosis due to dorsal muscles involvement and other skeletal deformations related to weak muscles of the limbs, breathing difficulties with paradoxical breathing, and bellshaped chest deformation due to the weakness of intercostal muscles (the diaphragm is usually not affected), swallowing and coughing problems related to hypotonia of throat muscles. The onset of symptoms in infants and young children is generally associated with poor weight gain. On the other hand, decreased physical activity results in a high risk of obesity in older patients. Patients are usually at increased risk of developing osteoporosis and frequent bone fractures. Due to breathing effort and autonomic system involvement, SMA patients frequently sweat excessively.1,18,19 Until recently, only symptomatic treatment of SMA was possible, including orthopedic operations (correction of scoliosis and limb deformities), ventilatory support, antibiotics during frequent respiratory infections (weakness of intercostal muscles and lack of proper coughing), naso-gastric tube or gastrostomy feeding for malnourished patients or those unable to swallow properly. Symptomatic treatment does not change the natural history of SMA and does not influence the loss of motor functions. However, it can extend life expectancy and improve the quality of life.14

Molecular Background of SMA

In more than 90% of all SMA cases, individual homozygous deletion of SMN1 gene located on the telomeric region of chromosome 5 is found.15,16,20 In a small number of SMA patients, the disease is caused by point mutations in the SMN1 gene.9,16,21 About 90% of SMN2 mRNA lacks exon 7, and protein translated from that transcript (named SMNΔ7) is shorter and non-functional. Thus, only 10-20% of normal SMN protein comes from the SMN2 gene.20 However, the number of SMN2 gene copies varies from 1 to even 8 in some individuals. It is known that the higher SMN2 copy number is related to the later onset of symptoms and slower disease progression.17 Patients with SMA 1 usually have 2 SMN2 copies, while SMA 2 and 3 patients have 3 copies or more.6,8 However, it is not a rule, and for example, patients with 4 SMN2 copies may rarely develop SMA type 1.4

Disease-Modifying Therapies

There are now 2 SMA treatment strategies: SMN1 gene replacement and increasingly functional SMN protein
production by the SMN2 gene. In 2016, the first disease-modifying treatment for SMA—nusinersen—was approved by the FDA, initiating a new SMA therapy era. Nusinersen is an antisense oligonucleotide which modulates splicing of the SMN2 mRNA transcript, thus increasing inclusion of exon 7 and production of full-length SMN protein. The drug is administered intrathecally with 3 loading doses given every 2 weeks, the fourth dose after 1 month, and then the maintenance doses are given every 4 months. Nusinersen, approved by the FDA in 2020, is an oral antisense oligonucleotide increasing the SMN protein production by the SMN2 gene. A similar agent, called branaplam, is still in clinical trials. In 2019, gene replacement therapy with onasemnogene abeparvovec-xioi (AVXS-101, trade name Zolgensma®) was approved by the FDA. It employs the AAV9 (adeno-associated virus type 9) vector to deliver the normal copy of the SMN1 gene. Due to its ability to cross the blood-brain barrier, it can be administered intravenously. Nusinersen, risdiplam, and onasemnogene abeparvovec-xioi showed their efficacy in SMA. Treatment with either of the compounds resulted in the disease activity stabilization not seen in the untreated cohorts. Moreover, a significant improvement in motor functions was observed in many cases. Both in clinical trials and now in clinical practice, different scales are used to assess the patients’ functional status objectively.

Motor Assessment Scales in SMA

According to the recommendations published in 2018, all SMA patients should undergo neurologic examinations every 6 months. Such examinations should include the assessment of motor functions according to an appropriate functional scale. The choice of a scale should be based on the patient’s age, SMA type, and current neurological status (Tables 2 and 3). The examinations using scales should be carried out by physiotherapists or physicians, employing tests based on the standard neurological examination.

The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP-INTEND)
The scale contains 16 items addressing the spontaneous movements, hand grip, head stabilization, flexion, and extension of the limbs. The state of the patients should be rated using the Brazelton Neonatal Behavioral Assessment Scale prior to examination with the CHOP-INTEND scale. It gives information on whether the patient’s abilities are state-dependent. The test should not be performed in hungry or tired patients. If the patient requires respiratory support, the test must not interrupt it. Every item is rated from 0 to 4 points in the CHOP-INTEND scale, and the maximum score is 64 points. In cases of asymmetric motor functions, the better side result should be reported. The complete CHOP-INTEND usually takes 10 to 15 minutes, but the exact time may vary according to the patient’s cooperation. The scale is relatively easy to use. It does not require any sophisticated equipment (only a toy to draw the patient’s attention and test the grip and a mirror useful in placing the child correctly on a caregiver’s lap) or special training. The CHOP-INTEND is the most popular scale used worldwide to assess SMA patients, and, therefore, may be used to compare the results obtained in different centers. It is used in daily clinical practice and clinical trials in SMA type 1 and non-sitting patients with other types of the disease. One of its limitations is relatively poor reliability in the youngest newborns and infants.

The Hammersmith Infant Neurologic Examination (HINE)
The Hammersmith Infant Neurologic Examination is a scale designed for children between 2 and 24 months of age. It is used to evaluate their ability to achieve motor milestones. The scale includes examining cranial nerves, posture, movements, tone, and reflexes. The maximum score is 26 points. The scale was invented to assess healthy children’s motor milestones and was validated in healthy populations only. The significant advantage of this scale is its simplicity and the short time required for the examination. However, the scale is not sensitive enough in the case of patients with a more severe disability.

The Hammersmith Infant Neurological Exam—Part 2 (HINE-2)
Like HINE, HINE-2 also evaluates motor milestones but is more focused on rating patients’ increments in each item. Thus it is more suitable for SMA patients who make no or very modest improvements in gaining the milestones. An examiner evaluates the patient’s head control, sitting, voluntary grasp, ability to kick, roll, crawl, stand, and walk. Points for every item are given for functions described in detail; for example, ability to kick gets 0 points for no kicking, 1 point is given for kicking horizontally, 2 for kicking upward, 3 for touching legs, and 4 for touching the toes. Every item has a different number of descriptive achievements (for example, for head control only 3), and the maximum score is 56 points. HINE-2 can be used as a tool to compare milestones achieved by non-SMA children and SMA patients.

It is widely used in SMA patients, but it still needs validation.

The Motor Function Measure-20 (MFM-20)
The Motor Function Measure (MFM) was validated in various neuromuscular disorders. It was initially designed for children aged 7 or more and has 32 items divided into functional domains. However, it was too strenuous for the majority of SMA patients. MFM-20 is a modified version of the MFM scale with some difficult items removed, making it suitable for younger children. The scale is composed of 20 items. It can be used in patients aged 2 or more.
| Name of the scale | Age | Target group | What does the test determine in particular | Advantages | Disadvantages | Validation in SMA |
|-------------------|-----|--------------|------------------------------------------|------------|--------------|------------------|
| CHOP-INTEND       | No lower or upper limit established<sup>30</sup> | Non-sitters<sup>30</sup> | The strength of the axial and peripheral muscles<sup>30</sup> | The child's behavioral state is taken into account<sup>30</sup> | Not sensitive enough | Yes<sup>30,31,32</sup> |
| HINE             | 2-24 months<sup>19</sup> | Non-sitters, sitters, and walkers<sup>19</sup> | Achieved milestones and cranial nerves<sup>19</sup> | Harmonizes with physiological motor development<sup>19</sup> | Age limit<sup>19</sup> | No |
| HINE-2           | 2-24 months<sup>33</sup> | Non-sitters, sitters, and walkers<sup>33</sup> | Focused on achieved milestones<sup>33</sup> | Rates the patient's increments<sup>10,33</sup> | Age limit<sup>34</sup> | Not enough data<sup>10,33</sup> |
| MFM-20           | >2 years | Sitters and walkers | Different patterns of weakness and different functional levels | Sensitive enough to distinguish between proximal and distal muscle weakness | Time-consuming | Yes (validated in neuromuscular disorders in general) |
| GMFM             | >5 years | Non-sitters, sitters, and walkers | A detailed assessment of muscle strength during motor development | Sensitive to distinguish even small changes in muscle strength | Too much focused on strength asymmetry | Yes |
| HFMS             | >30 months | Sitters and walkers | Upper and lower extremities and trunk muscles strength | Correlates with SMN2 copy number and age | Does not assess small muscles strength | No |
| HFMSE            | >2 years | Sitters and walkers | Gross motor function | Correlates with SMN2 copy number, CMAP, and FVC | Patient's cooperation is needed | Yes |
| RHS              | >1 year | Sitters and walkers | Gross motor function and motor milestones | Can be used when the patient achieves the ceiling effect on the HFMSE | Not enough data assessing test utility | No |
| 6-MWT            | >4 years | Walkers | Gait and fatigue | Assessment of different organs | Aggravating for weaker ambulant patients | Yes |
| RULM             | >30 months | Non-sitters, sitters, and walkers | Strength of upper limbs and precise movements | Assess abilities useful in everyday living | Assess only upper limbs | No |
| QMT              | >3 years | Non-sitters, sitters, and walkers | Strength of limbs muscles | The test is objective | Rates only a limited number of muscles | No |
| Neuromuscular GRO | No upper or lower limit | Non-sitters, sitters, and walkers | Muscle strength and motor development | Detailed items | Can cause fatigue | No |

Abbreviations: CHOP-INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE, Hammersmith Infant Neurologic Examination; HINE-2, Hammersmith Infant Neurologic Examination Section 2; MFM-20, Motor Function Measure 20; GMFM, Gross Motor Function Measure; HFMS, Hammersmith Functional Motor Scale; HFMSE, Expanded Hammersmith Functional Motor Scale; RHS, Revised Hammersmith Scale; 6MWT, 6-Minute Walk Test; RULM, Revised Upper Limb Module; QMT, Quantitative Muscle Testing; SMN2, Survival Motor Neuron Gene 2; CMAP, Compound Muscle Action Potential; FVC, Forced Vital Capacity; GRO, Gross Motor Outcome.
Table 3. Tests Recommended in Different Types of SMA.44

| Patient's best functional status | Recommended functional scale |
|---------------------------------|-------------------------------|
| Non-sitter                      | CHOP-INTEND, HINE             |
| Sitter                          | HFMSE, RULM, MFH             |
| Walker                          | 6-MWT, RULM, HFMSE           |

Abbreviations: CHOP-INTEND, Children's Hospital of Philadelphia Infant Test of Neuromuscular Disorders; HINE, Hammersmith Infant Neurologic Examination; HFMSE, Expanded Hammersmith Functional Motor Scale; RULM, Revised Upper Limb Module; MFM, Motor Function Measure; 6MWT, 6-Minute Walk Test.

Functional domains of MFM-20 include:

- D1—standing and transfers,
- D2—axial and proximal motor function,
- D3—distal motor function, thus, capturing different patterns of weakness (such as proximal or distal) and other functional levels (including the ability to walk).

Each item is scored from 0 (not able to initiate movement) to 3 (full performance of a task), and thus, 60 points are the maximum score on this scale.39

This scale’s major advantage is its relatively high sensitivity to differentiate changes in proximal and distal muscles.39 MFM-20 is most useful for children who can sit without support.40

The Gross Motor Function Measure (GMFM)

The Gross Motor Function Measure (designated at McMaster University) is a scale intended initially for children with cerebral palsy. Its validity was established by correlation with muscle strength—assessed by the Quantitative Muscle Testing (QMT) in patients from 5 (QMT is only valid from that age) to 18 years of age.38,41 It consists of 5 domains of items:

1. lying and rolling,
2. sitting,
3. crawling and kneeling,
4. standing,
5. walking, running, and jumping.38,41

The scale includes 88 items, and each item is scored from 0 to 3 points.38,41 The advantages of this scale include the discriminatory increments for small changes in strength and its flexibility as eliminating some items is allowed.41 It is essential for patients with hip contractures for whom the prone position is difficult or impossible to perform.41 Moreover, low scores correlate well with the use of ventilation support.41 The main disadvantage of GMFM is the relatively long time to perform the examination. Moreover, the scale is better suited for children with cerebral palsy (even though it is validated for SMA) and focused on asymmetry.41,42

The Hammersmith Functional Motor Scale (HFMS)

The Hammersmith Functional Motor Scale was designed in 2003 for children with SMA type 2 or 3 and aged >30 months.43 It consists of 20 items, each rated from 0 to 2 points, where 2 points are given when the activity is unaided, 1 when assistance is needed, and 0 when the patient is unable to perform the task.43 The maximum score is 40.43 Items are ordered from the easiest to the most difficult one.42 It takes about 15 minutes and tests the child’s ability to control the head, roll, achieve prop position, kneel, crawl, stand, and take at least 4 steps unaided.43 The high scores in HFMS were reported to correlate with a higher SMN2 copy number and patient’s age.41 Main at al. proposed to classify the HFMS results into decimals to describe the functional abilities of an SMA type 2 patient: a child with grade 2.7-2.9 should walk well in orthoses and be able to operate a manual wheelchair on even surfaces, grades of 2.8-2.9 indicate the ability to transfer to and from the wheelchair, whereas a child graded 2.1-2.3 can only stand in standing frames and needs assistance in daily activities.13,43 This scale is focused on patients with impaired ambulation, thus, in practice, it was suitable for mainly SMA type 2 patients.43 It has been modified several times as described below.

The Modified Hammersmith Functional Motor Scale (MHFMS)

There were several attempts to extend the HFMS to include both weaker and stronger patients. The Modified Hammersmith Functional Motor Scale was designed in 2006.32 It differs from the classic HFMS by making it easier for patients to perform and thus is suitable for children younger than 30 months and weaker, non-ambulant patients. Each item is scored from 0 to 2 points on a 20-item scale.32 The MHFMS allows the elimination of fatigue effects and postural changes on the results in the HFMS by changing the order of items.32,44 Notably, the intrarater, but not interrater, reliability of this scale in a group of non-ambulant patients with SMA type 2 and 3 and aged 2-12 is very good.43

The Expanded Hammersmith Functional Motor Scale (HFMSE)

The first version of this most commonly used modification of the HFMS, called the Expanded Hammersmith Functional Motor Scale (HFMSE), was presented at the Families of SMA meeting in 2005.38 This modification’s primary goal was to adapt HFMS for both SMA 2 and 3 patients to enable its use in clinical trials recruiting patients with both types of SMA.38 Since then, it has been upgraded. The scale is a fusion of HFMS with some items from the Gross Motor Function Measure (GMFM). The GMFM items were chosen to eliminate the ceiling effect in SMA 3 patients observed in the case of the GMFM test.38 The GMFM items included in the new scale were required to meet all of the following criteria:
1. at least one subject had to be scored in 3 of 4 scoring grades,
2. no ambiguous items,
3. items requiring no or minimal equipment,
4. clinically meaningful items,
5. not duplicated in HFMS.

As a result, 13 GMFM and 20 HFMS items were incorporated, making the 33-item HFMSE. The scoring was unified to 0-2 points, so the maximum score is 66 points.\textsuperscript{38,41} This scale rates gross motor functions.\textsuperscript{38,42} The score of the HFSME was reported to be positively correlated with the \textit{SMN2} copy number, forced vital capacity (FVC), and muscle strength in SMA patients.\textsuperscript{42} The advantage of the HFME over the HFMS is omitting the ceiling effect in the case of some SMA patients.\textsuperscript{38,42} The validity and reliability of HFMSE in SMA 2 and 3 patients were confirmed in numerous studies.\textsuperscript{38,41,45}

The Revised Hammersmith Scale (RHS)

The Revised Hammersmith Scale is the modified version of HFME and also adapted for SMA 2 and 3 patients.\textsuperscript{44} The idea of this modification emerged when Rasch analysis revealed that the original scale takes into consideration too dissimilar abilities and assesses patients bilaterally what makes the results less reliable.\textsuperscript{44,45} Item grouping removed the impact of position change in an order complying with the patient’s orientation.\textsuperscript{44} The RHS incorporated some modules from the World Health Organization (WHO) motor milestones.\textsuperscript{44} Those milestones include: sitting without support, hands- and- knees crawling, standing with assistance, walking with assistance, standing alone, and walking alone.\textsuperscript{46} It contains some modified elements from CHOP-INTEND, such as hip flexion from supine, in order to address the needs of frailer patients. It also takes elements from the North Star Ambulatory Assessment (NSAA), a test developed for patients with Duchenne muscular dystrophy (revised timed items included lifting the head from prone for a count of 3).\textsuperscript{44} The test consists of 36 items, and the maximum score is 69 points.\textsuperscript{44} However, further investigation is necessary to assess its validity.\textsuperscript{44}

The Revised Upper Limb Module (RULM)

The Revised Upper Limb Module is a modification of the Upper Limb Module (ULM), which was used in SMA patients aged >30 months who had low HFMSE scores due to advanced weakness or contractures in the lower limbs.\textsuperscript{47} The ULM, however, showed the ceiling effect. In order to modify it, some items from the Performance of Upper Limb (PUL)—a test used in Duchenne muscular dystrophy—were taken and subjected to Rasch analysis.\textsuperscript{47} The RULM rates only the upper limb, but it correlates very well with the ability to perform everyday activities. It consists of such items as putting a coin into a cup or elevating a cup to lips, picking a coin, bringing hand to shoulder, lifting weights, opening a zip lock, drawing a line on paper, and other tasks reflecting daily activities.\textsuperscript{47} The test is very sensitive in rating distal muscle strength. It contains 20 elements with a maximum score of 37 points. The patient chooses the preferred limb, and exercises are performed unilaterally. It takes approximately 20 minutes.\textsuperscript{47} The RULM can assess motor functions in non-walking SMA patients.\textsuperscript{47}

The 6-Minute Walk Test (6-MWT)

The 6-Minute Walk Test is applicable to SMA patients who can walk. It requires the patient’s cooperation, so it is not suitable for very young children.\textsuperscript{48} The patient is asked to walk 25 meters on a flat surface for 6 minutes as many times as possible. At least 10-minute rest is obligatory before the start of the test. No jogging or running is allowed. One can rest during the test but without sitting. Assistive devices such as orthoses or canes are not allowed.\textsuperscript{48} The analysis concerns:

- the distance covered during the 6 minutes of the tests,
- the distance covered during each minute of the test,
- time to complete each 25-meter walk,
- the number of falls,
- the difference between the distance walked in the first and last minute of the test.\textsuperscript{38}

Results are compared to those achieved by healthy participants matched according to gender, age, weight, and height.\textsuperscript{39} It should be noted that the result depends not only on muscle strength but also on the cardiopulmonary system’s functions.\textsuperscript{48,49}

Quantitative Muscle Testing (QMT)

Quantitative Muscle Testing (QMT) is an objective method to assess a patient’s muscle strength.\textsuperscript{41,50} It uses a dynamometer to examine different muscle groups (both flexors and extensors and both proximal and distal ones). Active contractions should be isometric and held for 5 s with a 10-15 s resting period.\textsuperscript{41,50} Each motion is repeated 3 times, and the best result is taken into account. The examiner measures the strength of each muscle group.\textsuperscript{41,50} Results are compared to those achieved in a healthy population.\textsuperscript{50}

The test is objective and reliable but requires the patient’s full cooperation with the examiner and is not suitable for feeble patients.\textsuperscript{50}

Neuromuscular Gross Motor Outcome

Neuromuscular Gross Motor Outcome (GRO) was designed for patients with neuromuscular diseases.\textsuperscript{51} It assesses whole body strength, motor development and function across the lifespan. It consists 50 items, each scored from 0 to 2 points.\textsuperscript{51} If asymmetry occurs only best side is considered. Examination starts from tasks requiring minimal muscle strength (like finger movements) to complicated complex movements (like ascending stairs or fast walk).\textsuperscript{51} It could be proper for different SMA patients.
The Use of the Scales in the Era of Treatment

None of the scales currently used in SMA patients alone is designed to assess everyday living functions, gross motor functions, and small muscle skills together, and none can be applied in all SMA individuals, including walkers, sitters, and nonsitters. Moreover, each scale rates patients in a different way, and it is not possible to translate the results from one scale to another.14

Until now, all scales have been used only to monitor a patient’s deterioration. In the era of disease-modifying treatments in SMA, there is a need for a reliable motor function scale enabling functional improvement assessment. It is of particular importance both in clinical trials and clinical practice, for example, when a justification for a change in therapy is required.

The clinical practice shows that the change in the CHOP-INTEND score frequently does not correspond with the improvement reported by the patients and their families. For example, the fingers’ fine movements or the ability to turn the head to the side are not included in the CHOP-INTEND scale. However, those small changes make a difference for many patients, as movements of the head make the observation of the environment possible, and finger movements can allow better communication using electronic devices. No scale includes the assessment of breathing and feeding of the patient despite the fact that it is known that any changes in time the mechanical ventilation is required or the time spent on eating meals may have a substantial effect on the quality of life. In daily practice, we frequently see patients who benefit from the therapy, but it cannot be reported using the scales. Therefore there is an unmet and urgent need to create a tool that could bypass the ceiling effect of the CHOP-INTEND scale.

Similar to SMA, amyotrophic lateral sclerosis (ALS) is also characterized by a progressive loss of motor function, therefore, some scales used in ALS might also be useful in SMA. The most popular functional scale used in ALS patients is the Tufts Quantitative Neuromuscular Exam (TQNE).52 It comprises 4 categories: assessment of pulmonary function, oropharyngeal function, timed motor activities, and isometric strength.52 However, those items require a patient’s cooperation and are too difficult for young children.

Manual Muscle Testing (MMT) is an example of a different approach to functional assessment in ALS and intensive care unit patients.53 This method relies on assessing the proximal and distal muscle strength performed by physiotherapists using palpation during a particular motor task.53 It cannot be applied in frail patients as it requires at least minimum muscle strength.

The Revised Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS-R) is a modification of the Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) used widely in clinical trials in ALS.54 The ALSFRS is a list of questions assessing the patient’s functions: speech, salivation, swallowing, handwriting, cutting food and handling utensils, dressing and hygiene, turning in bed and adjusting bed clothes, walking and climbing stairs. Each item is rated from 4 (normal function) to 0 (very advanced disability).54 The scale was validated for ALS patients and showed to correlate with the predicted survival of patients. The ALSFRS-R also includes questions about dyspnea, orthopnea, and respiratory insufficiency.54 This questionnaire may be of use in severely disabled patients with SMA. We suggest adding it as a sub-scale in patients with a very low CHOP-INTEND score, together with the assessment of cranial nerves. To be included in the CHOP-INTEND scale, the ranks for items from the ALSFRS should be changed to 0 for no function and 2 points for normal function. Table 4 presents our proposed subscale for severely affected SMA patients. The usefulness and reliability of this potential new scale require verification.

Conclusions

The progression of SMA symptoms can be assessed using different functional scales, but none is applicable to the whole spectrum of patients. In the era of disease-modifying therapies, the functional scales should evaluate the improvement in various SMA-related symptoms, including subtle changes in severely affected patients. Further efforts to establish a new

### Table 4. The Proposition of a Scale for Patients With a Very Low Number of Points in CHOP-INTEND.

| Action                        | 0                          | 1              | 2                          |
|-------------------------------|----------------------------|----------------|-----------------------------|
| Elevating eyebrows           | No movement                | Elevates with difficulty | Elevates high               |
| Grinning                      | No movement                | Teeth barely visible | Teeth exposed               |
| Protruding tongue             | No protrusion              | Tongue to the teeth line | Tongue crossing teeth line |
| Moving fingers                | No movement                | <5 finger can move | >5 fingers can move         |
| Moving toes                   | No movement                | <5 toes can move  | >5 toes can move            |
| Moving the head to the side   | No movement                | Able to move the head to the one side | Able to move the head to both sides |
| Speech                        | Cannot speak               | Speech difficult to understand | Speaks normally            |
| Salivation                    | Marked drooling            | Moderately excessive saliva | Normal                     |
| Swallowing                    | Cannot swallow, difficulty even with swallowing saliva | Choking when swallows, needs a change of food consistency | Normal                     |
| Respiratory insufficiency     | Requires permanent invasive ventilation | Requires intermittent non-invasive ventilation | No respiratory support needed |
tool that could be used both in clinical trials and daily practice are necessary.

Acknowledgments
We wish to acknowledge all our patients with spinal muscular atrophy and their caregivers.

Declaration of Conflicting Interests
The authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Funding
The authors received no financial support for the research, authorship, and/or publication of this article.

ORCID iD
Katarzyna Pierzchlewicz https://orcid.org/0000-0001-5084-8083

References
1. Kolb SJ, Kissel JT. Spinal muscular atrophy. Neurol Clin. 2015;33(4):831-846.
2. Emery AE. The nosology of the spinal muscular atrophies. J Med Genet. 1971;8(4):481-495.
3. Pearn JH, Carter CO, Wilson J. The genetic identity of acute infantile spinal muscular atrophy. Brain. 1973;96(3):463-470.
4. Vill K, Kölbl H, Schwartz O, et al. One year of newborn screening for SMA—Results of a German Pilot Project. J Neuromuscul Dis. 2019;6(4):503-515.
5. Sugarman EA, Nagan N, Zhu H, et al. Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72,400 specimens. Eur J Hum Genet. 2012;20(1):27-32.
6. Arnold ES, Fischbeck KH. Spinal muscular atrophy. Handb Clin Neurol. 2018;148:591-601.
7. Dubowitz V. Ramblings in the history of spinal muscular atrophy. Neuromuscular Disord. 2009;19(1):77-80.
8. Cano SJ, Mayhew A, Glanzman AM, et al. International coordinating committee for SMA clinical trials Rasch task force. Rasch analysis of clinical outcome measures in spinal muscular atrophy. Muscle Nerve. 2014;49(3):422-430.
9. Dubowitz V. Chaos in classification of the spinal muscular atrophies of childhood. Neuromuscul Disord. 1991;1(2):77-80.
10. Ustad T, Helbostad JL, Campbell SK, et al. Test-retest reliability of the Test of Infant Motor Performance Screening Items in infants at risk for impaired functional motor performance. Early Hum Dev. 2016;93:43-46.
11. De Sanctis R, Coratti G, Pasternak A, et al. Developmental milestones in type I spinal muscular. Neuromuscular Disorders. 2016;26(11):754-759.
12. Munsat TL. International SMA Collaboration. Neuromuscular Disorders. 1991;1(2):81.
13. Dubowitz V. Chaos in the classification of SMA: a possible resolution. Neuromuscular Disord. 1995;5(1):3-5.
14. Brzustowicz LM, Lehner T, Castilla LH, et al. Diagnosis and management of spinal muscular atrophy: Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care. Neuromuscular Disorders. 2018;28(2):103-115.
15. Brzustowicz LM, Lehner T, Castilla LH, et al. Genetic mapping of chronic childhood-onset spinal muscular atrophy to chromosome 5q11.2-13.3. Nature. 1990;344(6266):540-541.
16. Melki J, Lefebvre S, Burglen L, et al. De novo and inherited deletions of the 5q13 region in spinal muscular atrophies. Science. 1994;264(5164):1474-1477.
17. Swoboda KJ, Prior TW, Scott CB, et al. Natural history of denervation in SMA: relation to age, SMN2 copy number, and function. Ann Neurol. 2005;57(5):704-712.
18. Statland JM, Barohn RJ, McVey AL, Katz JS, Dimachkie MM, Dimachkie MM. Patterns of weakness. Neurol Clin. 2015;33(4):735-748.
19. Shababi M, Lorson CL, Rudnik-Schöneborn SS. Spinal muscular atrophy: a motor neuron disorder or a multi-organ disease? J Anat. 2014;224(1):15-28.
20. Parente V, Corti S. Advances in spinal muscular atrophy. Ther Adv Neurol Disord. 2018;11:1-13.
21. Prior TW, Kainerer AR, Hua Y, et al. A positive modifier of spinal muscular atrophy in the SMN2 gene. Am J Hum Genet. 2009;85(3):408-413.
22. Walsh S. Published 2016. Accessed March 09, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-first-drug-spinal-muscular-atrophy
23. Hoy SM. Nusinersen: a review in 5q spinal muscular atrophy. CNS Drugs. 2018;32(7):689-696.
24. Chiriboga CA. Nusinersen for the treatment of spinal muscular atrophy. Expert Rev Neurother. 2017;17(10):955-962.
25. Biogen Idec Ltd. Spinraza 12 mg solution for injection. Summary of Product Characteristics. 2020. Updated January 31, 2021.
26. Prior TW, Kainerer AR, Hua Y, et al. A positive modifier of spinal muscular atrophy in the SMN2 Gene. Am J Hum Genet. 2009;85(3):408-413.
27. O’Keefe L. Published 2020. Accessed March 09, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-oral-treatment-spinal-muscular-atrophy
28. An open label study of LMI070 (branaplam) in type 1 spinal muscular atrophy (SMA). Published 2014. Accessed March 09, 2021. https://clinicaltrials.gov/ct2/show/NCT02268552
29. Caccomo S. Published 2019. Accessed March 09, 2021. https://www.fda.gov/news-events/press-announcements/fda-approves-innovative-gene-therapy-treat-pediatric-patients-spinal-muscular-atrophy-rare-disease
30. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus Sham control in infantile-onset spinal muscular atrophy. N Engl J Med. 2017;377(18):1723-1732.
31. Tiziano FD, Bertini E, Messina S, et al. The Hammersmith functional score correlates with the SMN2 copy number: a multicentric study. Neuromuscular Disord. 2007;17(5):400-403.
32. Krosschell KJ Maczulski JA, Crawford TO, Scott C, Swoboda KJ. A modified Hammersmith functional motor scale for use in multicenter research on spinal muscular atrophy. Neuromuscular Disord. 2006, 16(7):417-426.
33. Romeo DM, Ricci D, Brogna C, Mercuri E. Use of the Hammersmith Infant Neurological Examination in infants with cerebral
palsy: a critical review of the literature. *Dev Med Child Neurol.* 2016;58(3):240-245.
34. Glanzman AM, Mazzone E, Main M, et al. The Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND): test development and reliability. *Neuromuscul Disord.* 2010;20(3):155-161.
35. Glanzman AM, McDermott MP, Montes J, et al. Validation of the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND). *Pediatr Phys Ther.* 2011;23(4):322-326.
36. Cech D, Biedry NL. Commentary on “Validation of the Children’s Hospital of Philadelphia Infant Test of Neuromuscular Disorders (CHOP INTEND)”. *Pediatr Phys Ther.* 2011;23(4):327.
37. Bishop KM, Montes J, Finkel RS. Motor milestone assessment of infants with spinal muscular atrophy using the Hammersmith infant neurological Exam-Part 2: Experience from a nusinersen clinical study. *Muscle Nerve.* 2018;57(1):142-146.
38. O’Hagen JM, Glanzman AM, McDermott MP, et al. An expanded version of the Hammersmith Functional Motor Scale for SMA II and III patients. *Neuromuscul Disord.* 2007;17(9-10):693-697.
39. Mazzone E, De Sanctis R, Fanelli L, et al. Hammersmith functional motor scale and motor function measure-20 in non ambulant SMA patients. *Neuromuscul Disord.* 2014;24(4):347-352.
40. Ricci F, Brusa C, Rossi F, et al. Functional assessment tools in children with Pompe disease: a pilot comparative study to identify suitable outcome measures for the standard of care. *Eur J Paediatr Neurol.* 2018;22(6):1103-1109.
41. Nelson L, Owens H, Hyman LS, Iannaccone ST; AmSMART Group. The gross motor function measure is a valid and sensitive outcome measure for spinal muscular atrophy. *Neuromuscul Disord.* 2006;16(6):374-380.
42. Glanzman AM, O’Hagen JM, McDermott MP, et al. Validation of the expanded Hammersmith functional motor scale in spinal muscular atrophy type II and III. *J Child Neurol.* 2011;26(12):1499-1507.
43. Main M, Kairon H, Mercuri E, Muntoni F. The Hammersmith functional motor scale for children with spinal muscular atrophy: a scale to test ability and monitor progress in children with limited ambulation. *Eur J Paediatr Neurol.* 2003;7(4):155-159.
44. Ramsey D, Scoto M, Mayhew A, et al. Revised Hammersmith Scale for spinal muscular atrophy: a SMA specific clinical outcome assessment tool. *PLoS One.* 2012;7(2):e0172346.
45. Cano SJ, Mayhew A, Glanzman AM, et al. Rasch analysis of clinical outcome measures in spinal muscular atrophy. *Muscle Nerve.* 2014;49(3):422-430.
46. Wijnhoven TM, de Onis M, Onyango AW, et al. Assessment of gross motor development in the WHO Multicentre Growth Reference Study. *Food Nutr Bull.* 2004;25(1_suppl_1):S37-45.
47. Mazzone ES, Mayhew A, Montes J, et al. Revised upper limb module for spinal muscular atrophy: development of a new module. *Muscle Nerve.* 2017;55(6):869-874.
48. Dunaway Young S, Montes J, Kramer SS, et al. Six-minute walk test is reliable and valid in spinal muscular atrophy. *Muscle Nerve.* 2016;54(5):836-842.
49. Ulrich S, Hildenbrand FF, Treder U, et al. Reference values for the 6-minute walk test in healthy children and adolescents in Switzerland. *BMC Pulm Med.* 2013;13(1):49.
50. Merlino L, Mazzone ES, Solari A, Morandi L. Reliability of handheld dynamometry in spinal muscular atrophy. *Muscle Nerve.* 2002;26(1):64-70.
51. Hospital Nationwide Children’s. Accessed March 09, 2021. https://www.nationwidechildrens.org/research/areas-of-research/center-for-gene-therapy/lowes-lab/neuromuscular-gross-motor-outcome-gro
52. Andres PL, Hedlund W, Finison L, Conlon T, Felmus M, Munsat TL. Quantitative motor assessment in amyotrophic lateral sclerosis. *Neurology.* 1986;36(7):937-941.
53. Ciesla N, Dinglas V, Fan E, Kho M, Kuramoto J, Needham D. Manual muscle testing: a method of measuring extremity muscle strength applied to critically ill patients. *J Vis Exp.* 2011;(50):2632.
54. Cedarbaum JM, Stambler N, Malta E, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. *J Neurol Sci.* 1999;169(1-2):13-21.